The Mercola laboratory is focused on developing new therapies for cardiovascular disease: their research combines in vitro disease models using cardiovascular cells generated from induced pluripotent stem cells with high throughput screening to define disease mechanisms, identify drug targets and develop drug leads.

Dr. So is interested in the diagnosis and treatment of neuromuscular diseases, including amyotrophic lateral sclerosis, neuropathies, myasthenia gravis, and electrophysiological characterization of these disorders.

Dr. Dubra's lab uses adaptive optics, a technology originally developed to observe distant stars and galaxies, to improve the optics of the eye so that individual retinal and blood cells can be visualized.

Dr. Enns's research interests include novel means of diagnosing and treating mitochondrial disorders, with an emphasis on antioxidant therapy, lysosomal disorders, and newborn screening by tandem mass spectrometry.

Dr. Lambert's research has focused on improving the visual outcomes of children with congenital cataracts.

Dr. Cowan's research looks to further our understanding of the pathophysiology of metabolic diseases, with the ultimate aim of improving patient testing and developing new therapeutic strategies.

Dr. Rockson is interested in the biology of lymphatic function in health and disease and has a specific interest in the lymphedema therapeutics and have created animal models to achieve high throughput screening.

Dr. Berry's clinical practice and his research both focus on choosing the most appropriate treatment and approach for patients based on the individual characteristics of the patient and their disease process.

Dr. Jamie Zeitzer is a circadian physiologist specializing in the understanding of the impact of light on circadian rhythms and other aspects of non-image forming light perception.

Dr. Valdez's group's research focuses in improving our diagnostic ability in common pediatric infectious and inflammatory conditions through optics.